Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?

In the last 10 years, there has been accumulating evidence that, even in a low serum testosterone environment, the androgen receptor (AR) remains the main driver of prostate cancer progression. This has led to the discovery and clinical development of new anti-androgens and androgen biosynthesis inh...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:European Medical Journal Oncology
المؤلف الرئيسي: Bertrand Tombal
التنسيق: مقال
اللغة:الإنجليزية
منشور في: European Medical Journal 2014-11-01
الموضوعات:
abiraterone
androgen receptor
anti-androgens
cross-resistance
Enzalutamide
الوصول للمادة أونلاين:http://emjreviews.com/wp-content/uploads/Sequential-Androgen-Receptor-Pathway-Inhibitor-in-Prostate-Cancer-Piling-Up-The-Benefits-or-a-Case-for-Cross-Resistance.pdf

الانترنت

http://emjreviews.com/wp-content/uploads/Sequential-Androgen-Receptor-Pathway-Inhibitor-in-Prostate-Cancer-Piling-Up-The-Benefits-or-a-Case-for-Cross-Resistance.pdf

مواد مشابهة